Long-Term Follow-Up of Patients with Birdshot Retinochoroidopathy Treated with Systemic Immunosuppression

Autor:	Justine R. Smith, James T. Rosenbaum, Matthias D. Becker, Michael S. Wertheim
Rok vydání:	2005
Předmět:	Adult Male medicine.medical_specialty Birdshot retinochoroidopathy medicine.drug_class medicine.medical_treatment Azathioprine Disease Autoimmune Diseases Uveitis Retinal Diseases medicine Humans Immunology and Allergy Glucocorticoids Retrospective Studies Immunosuppression Therapy business.industry Immunosuppression Choroid Diseases Syndrome Middle Aged Mycophenolic Acid medicine.disease Dermatology Surgery Ophthalmology Methotrexate Treatment Outcome Cyclosporine Etiology Corticosteroid Drug Therapy Combination Female business Immunosuppressive Agents Follow-Up Studies medicine.drug
Zdroj:	Ocular Immunology and Inflammation. 13:289-293
ISSN:	1744-5078 0927-3948
DOI:	10.1080/09273940490912407
Popis:	Birdshot retinochoroidopathy (BRC) is a rare uveitis syndrome of presumed autoimmune etiology. Therapy with systemic and periocular corticosteroids is of inconsistent efficacy, attendant with numerous potential long-term side effects. Corticosteroid-sparing strategies with agents such as cyclosporine A or azathioprine have been suggested for this disease.We retrospectively reviewed the medical charts of patients with BRC who were evaluated consecutively at a tertiary-care, referral-based North American uveitis clinic over a 15-year period.Eleven Caucasian patients (22 eyes) were diagnosed with BRC, representing approximately 1% of all cases seen at the uveitis clinic. HLA-A29 was positive in all 11 patients. We elected to treat five patients with azathioprine, methotrexate, cyclosporine A, mycophenolate mofetil, and/or IvIg, as well as systemic or periocular corticosteroid injections. The median period of follow-up for the five treated patients was six years (range: 8 months-13 years). Inflammation was reduced or stabilized in five of five patients.Although the definitive strategy for the management of BRC is unknown, control of intraocular inflammation and preservation of vision is possible with corticosteroid-sparing immunosuppressive agents.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f939d10c8dcd2b11ed87b470716220 https://doi.org/10.1080/09273940490912407 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.